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There are many types of biomarkers; the two common ones are biomarkers of
exposure and biomarkers of effect. The utility of a biomarker for estimating exposures
or predicting risks depends on the strength of the correlation between biomarker
concentrations and exposure/effects. In the current study, a combined exposure and
physiologically-based pharmacokinetic/pharmacodynamic (PBPK/PD) model of carbaryl
was used to demonstrate the use of computational modeling for providing insight
into the selection of biomarkers for different purposes. The Cumulative and Aggregate
Risk Evaluation System (CARES) was used to generate exposure profiles, including
magnitude and timing, for use as inputs to the PBPK/PD model. The PBPK/PD model
was then used to predict blood concentrations of carbaryl and urine concentrations of its
principal metabolite, 1-naphthol (1-N), as biomarkers of exposure. The PBPK/PDmodel also
predicted acetylcholinesterase (AChE) inhibition in red blood cells (RBC) as a biomarker of
effect. The correlations of these simulated biomarker concentrations with intake doses or
brain AChE inhibition (as a surrogate of effects) were analyzed using a linear regression
model. Results showed that 1-N in urine is a better biomarker of exposure than carbaryl
in blood, and that 1-N in urine is correlated with the dose averaged over the last 2 days
of the simulation. They also showed that RBC AChE inhibition is an appropriate biomarker
of effect. This computational approach can be applied to a wide variety of chemicals to
facilitate quantitative analysis of biomarker utility.
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INTRODUCTION
A biomarker is a substance that can be measured in an accessible
biological sample and is correlated to some metric or condi-
tion of interest in the body. Examples of accessible biological
samples include urine, blood, saliva, and hair; conditions of inter-
est include disease conditions, clinical states, evidence or extent
of exposure, and manifestation of biological effect. In environ-
mental sciences, two categories of biomarkers are widely used:
biomarkers of exposure and biomarkers of effect (WHO/IPCS,
1993; IUPAC, 2004). “Biomarkers of exposure” are markers that
infer exposures to xenobiotics. They may be the parent chemi-
cal itself, a metabolite, or an endogenous substance; at minimum,
the marker must exhibit a predictable relationship in response to
exposure (USEPA, 2014). In some cases, this predictable relation-
ship is strong enough to reconstruct exposures from measured
biomarker concentrations. In the majority of cases, however, this
relationship only allows for qualitative assessment such as trend
analysis. “Biomarkers of effect” are markers that are either known
to be directly associated with specific adverse outcomes (e.g.,
cholinergic poisoning, Kim et al., 2010; Marsillach et al., 2011),
or to be empirically associated with particular systemic effects
(e.g., oxidative stress, Peluso et al., 2013; Zhang et al., 2013).
Biomarkers of effect may be directly involved in the mode of
action, which describes the sequence of key events that link some
elevated tissue doses to an adverse toxicological and/or clinical
effect. The general distinctions between biomarkers of exposure
and biomarkers of effect are not always exclusive; some biomark-
ers may fall into both categories. For example, red blood cell
(RBC) cholinesterase inhibition has been considered to be both
a biomarker of exposure to organophosphate or carbamate pes-
ticides and an early biomarker of effect on inhibition of brain
cholinesterase activity (ATSDR, 1997; Garabrant et al., 2009).
Technological and scientific advances in analytical and clini-
cal chemistry have resulted in increased collection, analysis, and
reporting of human biomarkers in targeted cohort studies or
ongoing national surveys (e.g., the National Health and Nutrition
Examination Survey [NHANES] in the United States). There is
increased interest in utilizing these biomarker data to character-
ize/estimate exposures or to correlate them to health outcomes in
epidemiological studies. These applications are beyond the tradi-
tional uses of biomarkers, e.g., observing trends over time and
across different populations. As new areas of applications are
explored, it is critical to evaluate the utility of a specific biomarker
measurement for a particular purpose, either to reflect exposures
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to a chemical or to predict an association between exposures and
an adverse effect. Computational modeling is one of the tools
that can assist in evaluating the appropriateness of a biomarker’s
utility for a specific purpose.
In the current study, a physiologically based pharmacoki-
netic/pharmacodynamic (PBPK/PD) model for carbaryl (Yoon
et al., 2012, 2014) was used to evaluate various types of biomark-
ers for their utility as markers of external exposure or markers of
early effects. This PBPK/PD model quantitatively connects exter-
nal exposure (i.e., time course of oral exposure events) to the
concentration of the active species at the target organ (i.e., car-
baryl in brain), which in turn is connected to known key events
along the mode of action (e.g., acetylcholinesterase [AChE] inhi-
bition in RBC and in brain). In addition, the model predicts
the urinary concentration of the principal metabolite, 1-naphthol
(1-N), which has been used as a biomarker of exposure for
carbaryl (Meeker et al., 2007). This model was chosen for our
study for several reasons. First, carbaryl is a well-studied carba-
mate pesticide and its mechanism of action is generally agreed
upon (Carlock et al., 1999). Second, the PBPK/PD model for
carbaryl has the ability to predict both biomarkers of exposure
and biomarkers of effect. Third, this model includes sufficient
complexity (e.g., metabolism, urinary excretion) to highlight
the challenges in selecting an appropriate biomarkers for non-
persistent chemicals, while being simple enough to allow for
relatively straightforward analysis.
The PBPK/PD model was used to simultaneously track vari-
ous types of biomarkers and tissue concentrations as a function
of exposure doses, so that interdependent relationships between
exposure/effects and biomarkers could be examined in depth.
(Note: Time course data for a single simulated individual may
be found in Supplementary Figure 1). More specifically, the sim-
ulated biomarkers (e.g., concentrations of carbaryl and 1-N in
tissues or urine) were analyzed for correlations between external
exposure concentrations or brain cholinesterase inhibition, using
linear regression analysis, to determine their utility as markers for
either exposure or biological effects. The objective of this study is
to demonstrate the use of computational models to gain quantita-
tive insight into the utility of biomarkers for estimating exposure
and early biological events. Our approach to would be applicable
to other chemicals and will contribute to expanding the utility of
biomarkers beyond their traditional uses.
METHODS
The PBPK/PDmodel for carbaryl describes the disposition of car-
baryl and 1-N, the binding of carbaryl to cholinesterases in blood
and brain, and the urinary excretion of 1-N. The structure of the
model along with in vitro-based parameterization of the model
were described in detail in a previously published study (Yoon
et al., 2012). For this study, the model code was translated into
MATLAB® (R2013b version 8.2.0.701, MathWorks, Natick, MA).
The MATLAB code may be found in the Supplementary Material.
The m-files are available from the authors upon request.
The model has six compartments: GI tract, liver, fat, brain,
blood (which is further subdivided into plasma and RBC
sub-compartments), and a compartment for the rest of the
body. All tissue compartments were described in the model as
diffusion-limited. Absorption was included by adding the oral
dose directly to the GI tract compartment. Distribution was from
the GI tract to the liver and then to the blood. The blood compart-
ment communicated with the liver, brain, fat, and “rest of body”
compartments. Metabolism described in the model included
hydrolysis to 1-naphthol (which takes place in all compartments)
and metabolism of 1-naphthol to “other metabolites,” which are
not explicitly defined. The pharmacodynamic sub-models in the
brain and RBC compartments described the synthesis and degra-
dation of AChE, as well as binding of carbaryl to the AChE protein
and release of the decarbamylated 1-naphthol from the protein.
1-Naphthol was eliminated in the urine.
The Cumulative and Aggregate Risk Evaluation System
(CARES®, production version 3.0 build 1.3.4, ILSI Research
Foundation, Washington, D.C.) was used to generate a “virtual”
population of 500 individuals (based on the 1990 U.S. Census
data), between age 20 and 90 years old; and CARES was used
to estimate exposure to carbaryl via food and water (based on
the US Department of Agriculture’s 1994–1996, 1998 Continuing
Survey of Food Intake by Individuals). The output of the CARES
model includes the age, gender, body weight, and within-day
exposure profiles (time vs. carbaryl intake doses) for each indi-
vidual for 365 days. Urine output values (the volume of a urinary
void divided by the time between voids, a measure of the rate of
bladder filling) were randomly sampled from the NHANES 2009–
2010 dataset (CDC, 2014a). The urine output value is necessary
to convert moles of 1-naphthol eliminated in the urine (the out-
put of the simulation) into molar concentrations, as discussed
further below. CARES-simulated body weights and exposure pro-
files, along with the NHANES urine output values, served as
model inputs (Figure 1).
The PBPK/PD model was used to predict the time courses of
(1) a biomarker of exposure (as reported in NHANES 2007–2008
[CDC, 2014b]): urinary 1-N concentrations in spot samples; (2)
a potential biomarker of exposure: plasma carbaryl concentra-
tions in spot samples; (3) a biomarker of early effect: RBC AChE
inhibition; and (4) two inaccessible dose metrics in the target
tissue: 24-h average carbaryl concentrations in brain and brain
AChE inhibition. One week of exposure was simulated, with as
few as one and as many as 23 exposure events per day (median
of four per day) based on the CARES data. To simulate the spot
sampling of biomarkers in plasma or urine, sampling times were
selected from the final 24 h of the simulation using a uniform
distribution. For 1-N in urine, the time of the most recent void
was simulated from the same 24 h period, with the constraint
that it must be >1 h earlier than the sampling time. The spot
urinary 1-N concentration was calculated using the following
equation:
Spot Biomarker = molessampling −molesmrv(
tsampling − tmrv
)× urine output
where “Spot Biomarker” is the spot biomarker concentration of
1-N in the urine (nM), molessampling is the cumulative amount
of 1-N excreted by the time of sampling (nmol), molesmrv is the
cumulative amount of 1-N excreted by the time of the most recent
void (nmol), tsampling is the time of sampling (min), tmrv is the
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FIGURE 1 | Model inputs from CARES and NHANES. (A) Histogram of
subject body weights (kg); (B) histogram of urine flow rates (L/min) assigned
from NHANES; (C) probability density of the daily dose of carbaryl averaged
for each subject over the year (ng/kg BW/day) from CARES (solid line shows
the fitted distribution; geometric mean: 70.2 ng/kg/day, geometric standard
deviation: 1.84).
time of the most recent void (min), and “urine output” is the
value for the accumulation of urine in the bladder selected from
the NHANES 2009-2010 report.
A sensitivity analysis was performed on all 62 model param-
eters for five different model outputs: amount of urinary 1-N
(µmol), depression of brain AChE activity (%), depression of red
blood cell AChE activity (%), amount of carbaryl in brain tis-
sue (µmol), and concentration of carbaryl in blood plasma (µM)
(see Supplementary Tables 1, 2). A parameter was considered
to be sensitive if its normalized sensitivity coefficient was >0.1.
Normalized sensitivity coefficients were calculated as described
elsewhere (Peters, 2012). The sensitivity analysis was repeated at
three dose levels: the lowest average daily dose (29.7 ng/kg/day),
the highest average daily dose (426 ng/kg/day), and 1000 × the
highest average daily dose (426,000 ng/kg/day). No difference was
identified in those parameters that were found to be sensitive at
the three doses (Supplementary Table 1 contains a spreadsheet
listing which parameters were found to be sensitive for which
endpoints). Subsequently, a Monte Carlo analysis was conducted
to vary each sensitive parameter, as well as the time of sampling
(tsampling) and time of most recent void (tMRV ). Supplementary
Table 2 lists the central tendency (mean or geometric mean),
distribution width (standard deviation or geometric standard
deviation), and distribution type (normal or lognormal) that was
used for Monte Carlo analysis. All 500 individuals from CARES
were run 10 times each, which resulted in 5000 iterations for the
Monte Carlo analysis. Body weights, urine outputs, and exposure
profiles were the same for each individual over the 10 runs.
To determine the utility of various biomarkers to reflect expo-
sure concentrations or early biochemical changes, four sets of
linear regression analyses were conducted in this study.
(1) Examine the correlations between urinary 1-N concentra-
tions from spot samples and daily doses averaged over four
exposure periods to determine the appropriate time frame of
exposures that is most relevant to the measurement of 1-N
in urine. The four exposure periods examined were the prior
year, the prior week, the prior 2 days, and the prior 24 h.
(2) Compare the correlations between six model-output vari-
ables and the average daily dose over the last 2 days of
exposure (ng/kg/day). These six variables are spot 1-N con-
centrations in urine (a biomarker of exposure); 24-h averaged
carbaryl concentrations in blood (target tissue dose); spot
and 24-h averaged % AChE inhibition in RBC (an early bio-
chemical change); spot and 24-h averaged%AChE inhibition
in brain (a biochemical change).
(3) Compare the correlations between 24-h averaged % AChE
inhibition in RBC/brain with average daily doses, limiting
the dataset to only average daily doses over the last 2 days
of exposure that were>50 ng/kg/day.
(4) Examine the correlations between spot or 24-h averaged %
AChE inhibition in brain and four model-output variables
to determine which potential biomarker best reflects the
changes of AChE in brain. These four variables were spot
and 24-h averaged % AChE inhibition in RBC; spot 1-N
concentrations in urine; and spot carbaryl concentrations in
plasma.
(5) Compare the correlations between 24-h average brain con-
centration of carbaryl (target tissue dose) and two potential
biomarkers of exposure: spot 1-N concentrations in urine
and spot carbaryl concentrations in plasma.
Statistical analysis and graphics were produced using MATLAB®
and Microsoft Office Excel® (version 2007, Microsoft
Corporation, Redmond, WA).
RESULTS
Our regression analysis results showed that spot urinary 1-N
concentrations (nM) had no correlation with averaged doses
(ng/kg/day) from the past year (slope= −0.063, R2 = 0.00083),
the past week (slope= 0.39,R2 = 0.051), or the past 24 h (slope=
0.49, R2 = 0.13) (Figures 2A–C). The best exposure period
reflected by spot 1-N concentrations in urine was the average daily
dose from the past 2 days (slope= 0.81, R2 = 0.19) (Figure 2D).
Comparing to spot 1-N concentrations in urine (nM) (slope=
0.81, R2 = 0.19), 24-h averaged carbaryl concentrations in brain
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FIGURE 2 | Spot 1-N concentrations in urine (nM) vs. average daily
doses from four exposure periods (ng/kg/day) for 5000
simulations. (A) Exposure doses averaged over the past year.
(B) Exposure doses averaged over the past week. (C) Exposure dose
averaged over the 24 h prior to sampling. (D) Exposure dose averaged
over the past 2 days.
(pM) had a stronger correlation (slope = 0.88, R2 = 0.30)
with the average daily doses (ng/kg/day) from the past 2 days
(Figures 3A,B). Spot % AChE inhibition in brain (slope =
0.00033, R2 = 0.037) and in RBC (slope = 0.00034, R2 = 0.028)
had no correlation with the average daily doses (ng/kg/day) from
the past 2 days (Figures 3C,D). While there appeared to be no
correlations between 24-h averaged % AChE inhibition in brain
(slope = 0.00026, R2 = 0.054) and in RBC (slope = 0.00023,
R2 = 0.041) and the average daily doses (ng/kg/day) from the
past 2 days (Figures 3E,F), it was interesting to see that when the
analysis was limited to those individuals with average daily doses
higher than 50 ng/kg/day, a positive correlation emerged between
24-h averaged % AChE inhibition (for brain, slope = 0.0012,
R2 = 0.089; for RBC, slope = 0.0011, R2 = 0.096) and average
daily doses from the past 2 days (Figure 4).
The correlations between spot or 24-h average % AChE inhi-
bition in brain and in RBC were strong (slopes were > 0.76, R2
were > 0.65) (Figures 5A,B). Spot % AChE inhibition in brain
had no correlation with spot 1-N concentrations in urine or
spot carbaryl concentrations in plasma (slopes were< 0.0002, R2
were< 0.06) (Figures 5C,D).
The 24-h average brain concentration is a measure of the
“target tissue dose.” Spot 1-N concentrations in urine (slope =
0.54, R2 = 0.39) were more strongly correlated to the 24-h brain
carbaryl concentration than spot carbaryl plasma concentra-
tions were (slope = 0.35, R2 = 0.29) (Figure 6). The correlation
between spot 1-N concentrations in urine and 24-h averaged car-
baryl concentrations in brain (Figure 6A) was stronger than its
correlation with average daily doses of carbaryl (Figure 2A).
DISCUSSION
Biomarkers and biomonitoring are promising tools to link dif-
ferent elements along the source-to-outcome continuum for the
purpose of understanding the public health implications of expo-
sure to environmental chemicals (Sobus et al., 2011). Biomarkers
of exposure infer exposures to exogenous chemicals, and can
be used to complement environmental or personal monitor-
ing (USEPA, 2014). They can be useful in estimating variabil-
ity in exposures within a population or comparing groups of
individuals. Biomarkers of effect signify biological responses to
chemical exposures, and can be used to investigate chemical tox-
icity or changes in biological functions (USEPA, 2014). Despite
the potential utility in providing robust assessment of exposures
or health risks, there exists a need for developing methods to
evaluate whether a biomarker could be a marker for predicting
either exposure or effects. Two of the key considerations in eval-
uating the utility of a biomarker to assess exposures or effects
are (1) accounting for absorption, distribution, metabolism,
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FIGURE 3 | Correlations between six model-output variables and the
average daily doses over the last 2 days of exposure (ng/kg/day)
for 5000 simulations. (A) biomarker of exposure: spot 1-N in urine
(nM); (B) target tissue concentration: carbaryl concentrations in brain
averaged over the 24 h prior to sampling (pM); (C) Biomarker of early
biochemical changes at the target tissue: percent AChE inhibition in
brain tissue (baseline = 0%); (D) Biomarker of early biochemical
changes at peripheral tissue: percent AChE inhibition in red blood cells
(baseline = 0%); (E) Percent AChE inhibition in brain tissue averaged
over the last 24 h prior to the urine sampling time; (F) Percent AChE
inhibition in red blood cells averaged over the last 24 h prior to the
urine sampling time.
and excretion (ADME) characteristics and (2) estimating the
degree of correlation between the biomarker and the metric of
interest.
In order to use biomarkers in any application, accessibil-
ity and limit of detection (LOD) should always be considered
first. A biomarker must be sampled from an accessible biologi-
cal matrix, and the most common matrices are urine and blood.
Depending on the pharmacokinetic properties of a chemical, i.e.,
ADME characteristics, other matrices may need to be considered
to obtain a more “appropriate” biomarker for estimating expo-
sures or risks (Calafat and Needham, 2008). For example, some
chemicals lack any measurable excretion in urine or do not build
up to appreciable levels in blood due to their distribution charac-
teristics to peripheral compartments (e.g., highly fat-soluble com-
pounds), rapid elimination (e.g., volatile organic compounds), or
poor absorption (e.g., Olestra). For these chemicals, biomarkers
measured in hair, saliva, nail clippings, breast milk, or breath may
correlate better with exposure concentration and/or magnitude
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FIGURE 4 | Time-averaged (over 24h) % AChE inhibition for brain (x)
and RBC (♦) vs. average daily doses ≥50ng/kg/day from the last 2
days for 5000 simulations. For brain: slope = 0.0012, R2 = 0.089. For
RBC: slope = 0.0011, R2 = 0.096.
of effect. The detection limit can also have an important impact
on biomarker utility. Improvements in analytical capability would
be expected to lower the detection limit toward zero, but never
to zero. It is problematic to interpret biomarkers measurements
that contain a large number of non-detects (e.g., o-phenylphenol,
CDC, 2014a), either in the context of exposure or health risks.
Two common approaches for analyzing such data is to truncate
the distribution of biomarker concentrations at the LOD, or to
replace non-detects with some value relevant to the LOD (e.g.,
half of the LOD). It is important to bear in mind that these
approaches would suggest that the non-detects are missing values
or uninformative data rather than true values indicative of low- or
non-exposure. Computational studies skirt this issue somewhat
since very small values can still be predicted using the equations,
and there is no “detection” required. In addition, computational
simulations can be used to explore the highest exposure concen-
trations correlated to a biomarker concentration at the LOD. Due
to physiological differences and variability in the timing between
the exposure event(s) and biomarkers sampling, many different
levels of exposure can lead to the same biomarker concentration
(Grulke et al., 2014). If exposure at a dangerous level could poten-
tially lead to a biomarker concentration below the LOD, it could
suggest that a better analytical method is necessary.
ADME characteristics determine the quantitative relationship
that links the magnitude of exposures to biomarker levels, and
from there to the magnitude and incidence of adverse outcomes
at biological endpoints. For the example of carbaryl, the par-
ent compound is responsible for inhibiting cholinesterase and
the accessible biomarker is a urinary metabolite. The urinary
biomarker concentration is somewhat directly proportional to the
exposure, but its relationship to the effect (i.e., inhibition of AChE
in brain) may be directly or inversely proportional, depending
upon the relative rates of metabolism and urinary excretion. If an
individual has higher rate of metabolism from carbaryl to 1-N, or
higher rate of excretion of 1-N to urine, s/he may have a higher
urinary 1-N concentration but a lower carbaryl concentration,
and therefore a lower level of AChE inhibition in the brain. On
the other hand, if most people in a population have similar rates
of metabolism and excretion, higher urinary 1-N concentrations
may suggest higher exposure concentrations and higher carbaryl
concentrations, and therefore greater inhibition of AChE in the
brain.
The degree of correlation between biomarkers and exposure
or effects is often difficult to determine because such analysis
requires de novo experiments specifically designed for this pur-
pose. In reality, biomarker measurements are rarely collected in
conjunction with other exposure-related data. There exists a need
for systematically integrating various types of biomarkers with
other knowledge (e.g., ADME characteristics) to better inform
effects of exposure in the interest of promoting public health.
One of the most powerful techniques for integrating disparate
classes of knowledge is computational modeling (Sohn et al.,
2004; Georgopoulos et al., 2009; Mosquin et al., 2009; Phillips
et al., 2014). In the current study, a linked CARES-PBPK/PD
model was used to capture the dynamic relationships between
exposure, tissue concentrations, metabolism, biomarker concen-
trations in various matrices, and early biological effects. This
modeling approach provided an unparalleled capability to simu-
late chemical concentrations at any arbitrary time point, allowing
correlations between various metrics to be thoroughly explored.
Through this simulation process, biomarkers with the greatest
predictive or discriminatory power were identified to link to
exposure or biological effects, providing valuable insight into the
utility of biomarkers for different purposes.
In the current study, linear regression analysis was performed
to investigate the correlations between biomarker levels and expo-
sure concentrations or brain AChE inhibition. The results of
linear regression provide a rough, yet quantitative estimation
of two properties: sensitivity and variability. Here, sensitivity
is not used in the typical sense of biostatistics (i.e., the rate
of true positives for a binary variable), but in the sense com-
monly encountered in analytical chemistry: “the change in the
response of a system for a small change in the stimulus causing
the response” (Pardue, 1997). For highly “sensitive” biomarkers
of exposure, a small change in the exposure concentration corre-
sponds to a large change in the biomarker level. This result gives
discriminatory power to distinguish high levels of exposures from
low ones. Sensitivity is approximated as the slope of the regres-
sion. The slope is not only a measure of the direction of the
correlation (positive or negative), but can be used to determine
how useful a particular biomarker is for reconstructing exposure,
predicting acetylcholinesterase inhibition, or both. A slope near
zero means that the predictive value is poor, while a slope that is
greater in magnitude suggests stronger potential for the use of the
biomarker in a particular capacity. When the slope is near zero, it
is much more difficult to accurately reconstruct exposures from
biomarker data because a huge range of exposure is consistent
with a single biomarker concentration. Variability is rooted in
the natural differences between otherwise similar biological sys-
tems. Nothing in biology is an exact duplicate of another. When
two variables are correlated (e.g., intake of carbaryl vs. 1-N in
urine), natural variability may attenuate the correlation, moving
the slope toward zero. In this case, the R2 value can be used as an
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FIGURE 5 | Utility of peripheral markers to predict inhibition in the
target tissue (brain) for 5000 simulations. (A) Spot percent AChE inhibition
in the brain vs. spot percent AChE inhibition in red blood cells, taken at the
same time as the urine sampling; (B) 24-h averaged AChE inhibition in brain
vs. 24-h averaged AChE inhibition in RBC (time averaging was over the 24 h
prior to urine sampling); (C) Spot percent AChE inhibition in the brain vs. spot
1-N concentrations in urine (nM); (D) Spot percent AChE inhibition in the brain
vs. spot carbaryl concentrations in plasma (pM).
FIGURE 6 | (A) Utility of spot 1-N concentrations in urine to predict the concentration of carbaryl in the target tissue (brain) for 5000 simulations. (B) Utility of
spot carbaryl concentrations in brain to predict the concentration of carbaryl in the target tissue (brain).
indicator of the variability. Taken together, the slope and R2 value
can provide a reasonable indication of (1) whether a correlation
exists, (2) how sensitive a biomarker might be for its prospective
use (e.g., reconstructing exposure or predicting adverse effects),
and (3) how much variability is present.
We have intentionally avoided proposing cut-off values to
demarcate “good” vs. “bad” biomarkers. Instead, we propose that
the quantitative information derived from the regression analy-
sis be used to determine the utility of biomarkers on a relative,
rather than an absolute basis. For instance, urinary 1-N is a
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better biomarker of exposure than % RBC inhibition because its
R2 value is 0.19 instead of 0.028 (Figure 3). If RBC inhibition
data were all we had, however, then maybe it would suffice as a
(rough) estimate of exposure since there is a correlation, just not
a very strong one. R2 values are a statistical measure defined as
the fraction of the response variable variation that is explained
by the linear model (R2 = explained variation/total variation).
As an example, for the correlations presented in Figure 2, an
R2 value less than one implies that the variation in biomarker
measurements cannot be explained by intake doses alone.
While linear regression may at first seem too simplistic to offer
real insight, it is important to remember that this analysis would
not be possible without the use of a model that allows us to
match different metrics (blood concentration, urinary concentra-
tion, brain AChE inhibition, etc.) at exactly the same time points
for an individual. In real life scenarios, it is prohibitively expen-
sive to get large numbers of subjects and biological samples (such
as the 500 simulated subjects in this study and a time course of
blood concentrations) and unethical to perform certain experi-
ments (such as repeated brain biopsies to estimate a 24-h average
brain concentration and brain AChE inhibition). Our modeling
approach, even using the simple linear regression analysis in our
study, has enabled us to investigate the sensitivity of biomarkers
for their intended uses, and also to explore the sources of variabil-
ity (e.g., urine output) to gain insight regarding how to use these
biomarkers to estimate exposure or biological effects.
Biomarkers are generally collected as a snapshot of an indi-
vidual’s internal (e.g., blood) or excreted (e.g., urine) doses.
Thus, biomarkers of shorter half-life chemicals (e.g., phthalates)
often reflect daily variation in exposure patterns and magnitudes,
while biomarkers of longer half-life chemicals (e.g., mercury)
tend to reflect long-term average exposures (Clewell et al., 2008;
Sobus et al., 2011). Carbaryl has a relatively short half-life of
9 h (Feldmann and Maibach, 1974), so it is expected that its
biomarker of exposure, 1-N in urine, reflects recent exposures.
From our analysis, urinary 1-N concentrations had a very poor
correlation with average doses from the past year or past week.
This observation is expected because of carbaryl’s short half-life.
What was unexpected is that urinary 1-N concentrations had no
correlation with the average intake over the final 24 h period prior
to sampling; instead, the concentration of 1-Nwas a bettermarker
for the average daily dose over the final 2 days (Figure 2). This
finding indicates that accumulation of 1-N in urine does not only
reflect the clearance of carbaryl in the body, but multiple ADME
processes including the kinetic properties of metabolites. In this
case, the observed correlation is likely attributable to the relatively
slower excretion of 1-N compared to carbaryl.
In addition to 1-N concentrations in urine, correlations
between daily intakes of carbaryl and five other model outputs
were examined, including % AChE inhibition in RBC (an early
biological effect), %AChE inhibition in brain (a biological effect),
and 24-h averaged carbaryl concentrations in brain (target tissue
dose) (Figure 3). While carbaryl in brain has a stronger correla-
tion with average daily intake in the past 2 days when compared
to 1-N in urine, this variable cannot be a biomarker of expo-
sure since brain tissue is not readily available from living subjects.
(Note: For Figure 3, the daily intakes are averaged over the final
2 days of the simulation. See Supplementary Figure 2 for the
same correlations, but with the daily intake being the sum of
exposures over the 24 h period prior to sampling.) Percent AChE
inhibition in brain and RBC, either spot or 24-h averaged, were
found to have no correlation with daily intake of carbaryl aver-
aged over the past 2 days (Figures 2C–F). An exception was that
24-h average % AChE inhibition showed a positive correlation
with carbaryl intake at levels higher than 50 ng/kg/day (Figure 4).
This observation implies that the lack of correlation was caused by
no inhibition of AChE at lower intake levels. The mode of action
for carbaryl toxicity involves carbaryl inhibiting AChE in the
brain, which then can result in cholinergic overstimulation and
subsequently lead to autonomic and neuromuscular dysfunction.
AChE inhibition in the brain is therefore a marker of early bio-
chemical changes before an adverse clinical effect occurs, but this
marker is not measurable in humans. In the current study, three
potential biomarkers were evaluated for their utility to represent
AChE inhibition in brain. Our findings (Figures 5A,B) were con-
sistent with several studies conducted in laboratory animals where
good concordance was found between brain and RBC AChE inhi-
bition (McDaniel et al., 2007; Moser et al., 2010). This result
further supports the use of RBC AChE as an ideal biomarker of
early biochemical changes, especially since assays already exist to
measure RBC AChE activity, and RBC AChE is generally more
sensitive than brain AChE (Carlock et al., 1999; Moser et al.,
2010).
One of the principal advantages of PBPK modeling to toxicol-
ogists is that it enables the estimation of internal concentrations
of chemicals/metabolites or biological changes that are not acces-
sible in humans. In this study, the PBPK/PD model was used
to predict the target tissue dose (carbaryl concentrations in the
brain), which is a better surrogate to adverse effects than are
the intake doses. Our analyses suggest that spot 1-N concentra-
tions in urine are better than spot carbaryl concentrations in
plasma at predicting 24-h averaged carbaryl concentrations in
brain (spot 1-N vs. average brain concentrations: slope = 0.54,
R2 = 0.39; spot plasma vs. average brain concentrations; slope =
0.35, R2 = 0.29; Figure 6). The common assumption for chemi-
cals with short half-lives is that a blood biomarker is better than a
urine biomarker; however, our results indicate that this assump-
tion is not always true. Part of the reason for our observation
relates to the nature of “spot” samples, which are collected at
a specific moment in time. When a spot urine sample is col-
lected, it contains chemicals accumulated in the bladder, so it
is actually time-averaged to some extent. In contrast, a plasma
sample is considered a true “snapshot” of the instantaneous con-
centration of a chemical in blood at a particular time point. Since
urinary biomarkers inherently integrate exposures through time,
they may be better correlated to biological effects than a spot
plasma concentration.
The current study demonstrates the use of computational
models to evaluate the utility of various biomarkers. One caveat
of the findings in this study is that the best biomarker of exposure,
1-N in urine, and the best biomarker of biochemical changes,
RBCAChE inhibition, are both non-specific biomarkers. For 1-N,
this compound is a metabolite of both carbaryl and naphthalene,
and therefore 1-N found in urine can be a result of exposure
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to carbaryl, naphthalene, or both. Specificity can be achieved
in biomonitoring studies by concurrently measuring 2-naphthol
(2-N) concentrations, since 2-N is a metabolite of naphthalene
but not of carbaryl (Meeker et al., 2007). Since our model does
not take naphthalene exposure into account, our conclusions rep-
resent the case in which exposure to naphthalene is negligible. For
RBC AChE, this enzyme can be inhibited by several chemicals.
The most commonly known inhibitors are the organophosphate
pesticides. A test of RBC AChE inhibition cannot distinguish
between inhibition due to carbaryl or organophosphates, so again
a concurrent measurement of another biomarker, such as 1-N, is
necessary to provide some specificity. Of course, from a clinical
standpoint, since cholinergic poisonings are all treated similarly
it may not be crucial in every case to establish the identity of the
toxicant, but from a scientific standpoint it is essential to under-
stand the fundamental limitations of the biomarker approach
to estimating exposures and predicting effects based on a single
biomarker measurement.
As demonstrated in this study, PBPK/PD models, which are
unique in their ability to incorporate a wide variety of research
findings, are well-suited for fostering improved use of biomarkers.
Computational models provide new avenues for the analysis and
interpretation of biomarker data which will contribute to a more
detailed understanding of chemical exposures and biochemical
effects in human populations. In addition, they can facilitate
the discovery of new biomarkers. To realize the full potential of
biomonitoring surveys, biomarker data must be combined with
any and all available tools to support a fuller understanding of
the linkages between exposure, internal dose, and toxicological
effect.
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